Analyst Coverage| Firm | Analyst | Phone | | Argus Research Company | David Tuong | 212-425-5467 | | Bank of America Merrill Lynch | Derik de Bruin | 646-855-3100 | | Barclays | Jack Meehan | 212-526-3909 | | Canaccord Genuity | Mark Massaro | 617-371-3769 | | Citi | Ralph Giacobbe | 212-816-0679 | | Craig-Hallum | Kevin Ellich | 612-334-8228 | | Credit Suisse | AJ Rice | 212 325 8134 | | Deutsche Bank | Dan Leonard | 212 250-9965 | | Evercore ISI | Ross Muken | 212-653-9023 | | Goldman Sachs & Co. | Patrick Donnelly | 212-902-6393 | | J.P. Morgan | Lisa Gill | 212-483-2323 | | Jefferies & Co. | Brian Tanquilut | 615-963-8338 | | KeyBanc Capital Markets | Donald Hooker | 917-368-2378 | | Mizuho Securities USA Inc. | Ann Hynes | 617-235-1741 | | Morgan Stanley | Ricky Goldwasser | 212-761-4097 | | Morningstar Inc,. | Deborah Wang | 312-384-3937 | | Piper Jaffray | William Quirk | 612-303-6858 | | Robert W. Baird | Eric Coldwell | 312-609-5467 | | Suntrust Robinson Humphrey | David MacDonald | 617-345-6534 | | William Blair & Company, L.L.C. | Matthew Larew | 312-364-8242 |
|
 |
Quest Diagnostics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Quest Diagnostics's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Quest Diagnostics or its management. Quest Diagnostics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. | | 1-Strong Buy | 3 | | 2-Buy | 5 | | 3-Hold | 11 | | 4-Underperform | 0 | | 5-Sell | 1 |
|
| Mean Recommendation: 2.5
| | Sell |  | Strong Buy |
|
|
|
|
|
| Analyst Forecasts - EPS | | | Last Month Revisions | | Fiscal Period | | Mean | High | Low | Median | # of Estimates | #Up | #Down | Mean % Change | | Annual | Dec 21 | 7.18 | 7.58 | 6.69 | 7.19 | 10 | 0 | 3 | -2.01 | | Annual | Dec 20 | 6.75 | 7.06 | 6.60 | 6.75 | 19 | 0 | 14 | -2.16 | | Annual | Dec 19 | 6.47 | 6.70 | 6.40 | 6.45 | 19 | 1 | 16 | -1.47 | | Quarterly | Mar 19 | 1.38 | 1.68 | 1.30 | 1.37 | 18 | 0 | 16 | -14.05 | | Quarterly | Jun 19 | 1.72 | 1.83 | 1.63 | 1.70 | 18 | 2 | 13 | -2.08 | | Quarterly | Sep 19 | 1.71 | 1.76 | 1.62 | 1.71 | 18 | 12 | 3 | 2.96 | | Quarterly | Dec 19 | 1.66 | 1.83 | 1.53 | 1.67 | 18 | 11 | 2 | 4.67 | | Long Term Growth | | 5.93 | 7.00 | 4.50 | 6.80 | 5 | 1 | 2 | -17.71 |
| Actuals - EPS | | | | Reported EPS | Mean Estimate | Surprise % Change | | Annual | Dec 18 | 6.31 | 6.33 | -0.38 | | Annual | Dec 17 | 5.67 | 5.65 | 0.40 | | Annual | Dec 16 | 5.15 | 5.10 | 0.96 | | Quarterly | Dec 18 | 1.36 | 1.37 | -0.52 | | Quarterly | Sep 18 | 1.68 | 1.68 | 0.19 | | Quarterly | Jun 18 | 1.75 | 1.76 | -0.36 | | Quarterly | Mar 18 | 1.52 | 1.49 | 1.92 |
| Data Provided by Thomson Reuters |
|
